Current drug treatment, chronic and acute

Clinics in Chest Medicine

Volumn 35, Issue 1, 2014, Pages 177-189

  Calverley, Peter ^a  

^a UNIVERSITY HOSPITAL AINTREE   (United Kingdom)

Author keywords

Bronchodilators; COPD and exacerbations; Inhaled corticosteroids

Indexed keywords

BRONCHODILATORS; COPD AND EXACERBATIONS; INHALED CORTICOSTEROIDS;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; AMINOPYRIDINES; ANTI-BACTERIAL AGENTS; BENZAMIDES; BRONCHODILATOR AGENTS; CYCLOPROPANES; DRUG THERAPY, COMBINATION; EVIDENCE-BASED MEDICINE; FORCED EXPIRATORY VOLUME; HUMANS; MUSCARINIC ANTAGONISTS; PHOSPHODIESTERASE 4 INHIBITORS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84893445893     PISSN: 02725231     EISSN: 15578216     Source Type: Journal    
DOI: 10.1016/j.ccm.2013.09.009     Document Type: Review

References (90)

1. Celli B.R., MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004, 23(6):932-946.
2. Rabe K.F., Hurd S., Anzueto A., et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007, 176(6):532-555.
3. Chronic obstructive pulmonary disease. National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care. Thorax 2004, 59(Suppl 1):1-232. National Collaborating Centre for Chronic Conditions.
4. Lightowler J.V., Wedzicha J.A., Elliott M.W., et al. Non-invasive positive pressure ventilation to treat respiratory failure resulting from exacerbations of chronic obstructive pulmonary disease: cochrane systematic review and meta-analysis. BMJ 2003, 326(7382):185.
5. Chakrabarti B., Angus R.M., Agarwal S., et al. Hyperglycaemia as a predictor of outcome during non invasive ventilation in decompensated COPD. Thorax 2009, 64(10):857-862.
6. Albert P., Calverley P.M. Drugs (including oxygen) in severe COPD. Eur Respir J 2008, 31(5):1114-1124.
7. O'Donnell D.E., D'Arsigny C., Webb K.A. Effects of hyperoxia on ventilatory limitation during exercise in advanced chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001, 163(4):892-898.
8. Lacasse Y., Lecours R., Pelletier C., et al. Randomised trial of ambulatory oxygen in oxygen-dependent COPD. Eur Respir J 2005, 25(6):1032-1038.
9. Stevenson N.J., Calverley P.M. Effect of oxygen on recovery from maximal exercise in patients with chronic obstructive pulmonary disease. Thorax 2004, 59(8):668-672.
10. Suissa S., Dell'Aniello S., Ernst P. Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality. Thorax 2012, 67(11):957-963.
11. Parker C.M., Voduc N., Aaron S.D., et al. Physiological changes during symptom recovery from moderate exacerbations of COPD. Eur Respir J 2005, 26(3):420-428.
12. Stevenson N.J., Walker P.P., Costello R.W., et al. Lung mechanics and dyspnea during exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005, 172(12):1510-1516.
13. Austin M.A., Wills K.E., Blizzard L., et al. Effect of high flow oxygen on mortality in chronic obstructive pulmonary disease patients in prehospital setting: randomised controlled trial. BMJ 2010, 341:c5462. 10.1136/bmj.c5462.:c5462.
14. Gross N.J., Petty T.L., Friedman M., et al. Dose response to ipratropium as a nebulized solution in patients with chronic obstructive pulmonary disease. A three-center study. Am Rev Respir Dis 1989, 139(5):1188-1191. [see comments].
15. Moayyedi P., Congleton J., Page R.L., et al. Comparison of nebulised salbutamol and ipratropium bromide with salbutamol alone in the treatment of chronic obstructive pulmonary disease. Thorax 1995, 50(8):834-837.
16. Hadcroft J., Calverley P.M. Alternative methods for assessing bronchodilator reversibility in chronic obstructive pulmonary disease. Thorax 2001, 56(9):713-720.
17. Parshall M.B., Schwartzstein R.M., Adams L., et al. An official American Thoracic Society statement: update on the mechanisms, assessment, and management of dyspnea. Am J Respir Crit Care Med 2012, 185(4):435-452.
18. McKay S.E., Howie C.A., Thomson A.H., et al. Value of theophylline treatment in patients handicapped by chronic obstructive lung disease. Thorax 1993, 48(3):227-232.
19. Rice K.L., Leatherman J.W., Duane P.G., et al. Aminophylline for acute exacerbations of chronic obstructive pulmonary disease. A controlled trial. Ann Intern Med 1987, 107(3):305-309.
20. Duffy N., Walker P., Diamantea F., et al. Intravenous aminophylline in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial. Thorax 2005, 60(9):713-717.
21. Qiu Y., Zhu J., Bandi V., et al. Biopsy neutrophilia, neutrophil chemokine and receptor gene expression in severe exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003, 168(8):968-975.
22. Niewoehner D.E., Erbland M.L., Deupree R.H., et al. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. NEngl J Med 1999, 340(25):1941-1947.
23. Davies L., Angus R.M., Calverley P.M. Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial. Lancet 1999, 354(9177):456-460.
24. Aaron S.D., Vandemheen K.L., Hebert P., et al. Outpatient oral prednisone after emergency treatment of chronic obstructive pulmonary disease. NEngl J Med 2003, 348(26):2618-2625.
25. Sayiner A., Aytemur Z.A., Cirit M., et al. Systemic glucocorticoids in severe exacerbations of COPD. Chest 2001, 119(3):726-730. [see comments].
26. Thompson W.H., Nielson C.P., Carvalho P., et al. Controlled trial of oral prednisone in outpatients with acute COPD exacerbation. Am J Respir Crit Care Med 1996, 154(2 Pt 1):407-412.
27. Decramer M., de Bock V., Dom R. Functional and histologic picture of steroid-induced myopathy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1996, 153(6 Pt 1):1958-1964.
28. Wedzicha J.A., Seemungal T.A. COPD exacerbations: defining their cause and prevention. Lancet 2007, 370(9589):786-796.
29. Calverley P.M., Stockley R.A., Seemungal T.A., et al. Reported pneumonia in patients with COPD: findings from the INSPIRE study. Chest 2011, 139(3):505-512.
30. Daniels J.M., Snijders D., de Graaff C.S., et al. Antibiotics in addition to systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2010, 181(2):150-157.
31. Anthonisen N.R., Manfreda J., Warren C.P., et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987, 106(2):196-204.
32. Rothberg M.B., Pekow P.S., Lahti M., et al. Antibiotic therapy and treatment failure in patients hospitalized for acute exacerbations of chronic obstructive pulmonary disease. JAMA 2010, 303(20):2035-2042.
33. Vestbo J., Hurd S.S., Agusti A.G., et al. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease, GOLD executive summary. Am J Respir Crit Care Med 2013, 187(4):347-365.
34. O'Reilly J., Jones M.M., Parnham J., et al. Management of stable chronic obstructive pulmonary disease in primary and secondary care: summary of updated NICE guidance. BMJ 2010, 340:c3134. 10.1136/bmj.c3134.:c3134.
35. Bateman E.D., Hurd S.S., Barnes P.J., et al. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J 2008, 31(1):143-178.
36. Hattotuwa K.L., Gizycki M.J., Ansari T.W., et al. The effects of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary disease: a double-blind, placebo-controlled biopsy study. Am J Respir Crit Care Med 2002, 165(12):1592-1596.
37. Bourbeau J., Christodoulopoulos P., Maltais F., et al. Effect of salmeterol/fluticasone propionate on airway inflammation in COPD: a randomised controlled trial. Thorax 2007, 62(11):938-943.
38. Lapperre T.S., Snoeck-Stroband J.B., Gosman M.M., et al. Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2009, 151(8):517-527.
39. Vestbo J., Sorensen T., Lange P., et al. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 1999, 353(9167):1819-1823.
40. Pauwels R.A., Lofdahl C.G., Laitinen L.A., et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. NEngl J Med 1999, 340(25):1948-1953.
41. The Lung Health Study Research Group Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. NEngl J Med 2000, 343:1902-1909.
42. Burge P.S., Calverley P.M., Jones P.W., et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000, 320(7245):1297-1303.
43. Sutherland E.R., Allmers H., Ayas N.T., et al. Inhaled corticosteroids reduce the progression of airflow limitation in chronic obstructive pulmonary disease: a meta-analysis. Thorax 2003, 58(11):937-941.
44. Soriano J.B., Sin D.D., Zhang X., et al. Apooled analysis of FEV1 decline in COPD patients randomized to inhaled corticosteroids or placebo. Chest 2007, 131(3):682-689.
45. Albert P., Agusti A., Edwards L., et al. Bronchodilator responsiveness as a phenotypic characteristic of established chronic obstructive pulmonary disease. Thorax 2012, 67(8):701-708.
46. Rabe K.F., Bateman E.D., O'donnell D., et al. Roflumilast-an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2005, 366(9485):563-571.
47. Fabbri L.M., Calverley P.M., Izquierdo-Alonso J.L., et al. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with long acting bronchodilators: two randomised clinical trials. Lancet 2009, 374(9691):695-703.
48. Kardos P., Wencker M., Glaab T., et al. Salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007, 175(2):144-149.
49. Wedzicha J.A., Calverley P.M., Seemungal T.A., et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 2008, 177(1):19-26.
50. Calverley P.M., Anderson J.A., Celli B., et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. NEngl J Med 2007, 356(8):775-789.
51. Kiri V.A., Pride N.B., Soriano J.B., et al. Inhaled corticosteroids in chronic obstructive pulmonary disease: results from two observational designs free of immortal time bias. Am J Respir Crit Care Med 2005, 172(4):460-464.
52. Ferguson G.T., Calverley P.M., Anderson J.A., et al. Prevalence and progression of osteoporosis in patients with COPD. Results from TORCH. Chest 2009, 136(6):1456-1465.
53. Crim C., Calverley P.M., Anderson J.A., et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. Eur Respir J 2009, 34(3):641-647.
54. Dransfield M.T., Bourbeau J., Jones P.W., et al. Oncedaily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. Lancet Respir Med 2013, 1(30):210-223.
55. Sin D.D., Tashkin D., Zhang X., et al. Budesonide and the risk of pneumonia: a meta-analysis of individual patient data. Lancet 2009, 374(9691):712-719.
56. Garcha D.S., Thurston S.J., Patel A.R., et al. Changes in prevalence and load of airway bacteria using quantitative PCR in stable and exacerbated COPD. Thorax 2012, 67(12):1075-1080.
57. Vestbo J., Anderson J.A., Calverley P.M., et al. Bias due to withdrawal in long-term randomised trials in COPD: evidence from the TORCH study. Clin Respir J 2011, 5(1):44-49.
58. Kesten S., Plautz M., Piquette C.A., et al. Premature discontinuation of patients: a potential bias in COPD clinical trials. Eur Respir J 2007, 30(5):898-906.
59. Calverley P.M., Rennard S.I. What have we learned from large drug treatment trials in COPD?. Lancet 2007, 370(9589):774-785.
60. Qaseem A., Wilt T.J., Weinberger S.E., et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med 2011, 155(3):179-191.
61. Spencer S., Calverley P.M., Burge P.S., et al. Health status deterioration in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001, 163(1):122-128.
62. Spencer S., Calverley P.M., Burge P.S., et al. Impact of preventing exacerbations on deterioration of health status in COPD. Eur Respir J 2004, 23(5):698-702.
63. Bestall J.C., Paul E.A., Garrod R., et al. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax 1999, 54(7):581-586.
64. Jones P.W., Harding G., Berry P., et al. Development and first validation of the COPD assessment test. Eur Respir J 2009, 34(3):648-654.
65. Hurst J.R., Vestbo J., Anzueto A., et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. NEngl J Med 2010, 363(12):1128-1138.
66. Han M.K., Muellerova H., Curran-Everett D., et al. GOLD 2011 disease severity classification in COPDGene: a prospective cohort study. Lancet Respir Med 2013, 1:43-49.
67. Jones P., Adamek L., Nadeau G., et al. Comparisons of health status scores with MRC grades in a primary care COPD population: implications for the new GOLD 2011 classification. Eur Respir J 2013, 42(3):647-654.
68. Vogelmeier C., Hederer B., Glaab T., et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. NEngl J Med 2011, 364(12):1093-1103.
69. Jones P.W., Barnes N., Vogelmeier C., et al. Efficacy of indacaterol in the treatment of patients with COPD. Prim Care Respir J 2011, 20(4):380-388.
70. Donohue J.F., Fogarty C., Lotvall J., et al. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med 2010, 182(2):155-162.
71. Jenkins C.R., Jones P.W., Calverley P.M., et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study. Respir Res 2009, 10:59.
72. Aaron S.D., Vandemheen K.L., Fergusson D., et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2007, 146(8):545-555.
73. Vogelmeier C., Bateman E.D., Pallante J., et al. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study. Lancet Respir Med 2013, 1(1):51-60.
74. Wedzicha J.A., Decramer M., Ficker J.H., et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respir Med 2013, 1(3):199-209.
75. Welte T., Miravitlles M., Hernandez P., et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009, 180(8):741-750.
76. Calverley P.M., Rabe K.F., Goehring U.M., et al. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 2009, 374(9691):685-694.
77. Rennard S.I., Calverley P.M., Goehring U.M., et al. Reduction of exacerbations by the PDE4 inhibitor roflumilast-the importance of defining different subsets of patients with COPD. Respir Res 2011, 12:18.
78. Bateman E.D., Rabe K.F., Calverley P.M., et al. Roflumilast with long-acting beta2-agonists for COPD: influence of exacerbation history. Eur Respir J 2011, 38(3):553-560.
79. Calverley P.M., Martinez F.J., Fabbri L.M., et al. Does roflumilast decrease exacerbations in severe COPD patients not controlled by inhaled combination therapy? The REACT study protocol. Int J Chron Obstruct Pulmon Dis 2012, 7:375-382. 10.2147/COPD.S31100.
80. Albert P., Calverley P. APEACE-ful solution to COPD exacerbations?. Lancet 2008, 371(9629):1975-1976.
81. Calverley P.M., Anderson J.A., Celli B., et al. Cardiovascular events in patients with COPD: TORCH study results. Thorax 2010, 65(8):719-725.
82. Kesten S., Jara M., Wentworth C., et al. Pooled clinical trial analysis of tiotropium safety. Chest 2006, 130(6):1695-1703.
83. Stephenson A., Seitz D., Bell C.M., et al. Inhaled anticholinergic drug therapy and the risk of acute urinary retention in chronic obstructive pulmonary disease: a population-based study. Arch Intern Med 2011, 171(10):914-920.
84. Jones P.W., Singh D., Bateman E.D., et al. Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study. Eur Respir J 2012, 40(4):830-836.
85. Celli B., Decramer M., Kesten S., et al. Mortality in the 4 year trial of tiotropium (UPLIFT) in patients with COPD. Am J Respir Crit Care Med 2009, 180(10):948-955.
86. Singh S., Loke Y.K., Enright P.L., et al. Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trials. BMJ 2011, 342:d3215. 10.1136/bmj.d3215.:d3215.
87. Dong Y.H., Lin H.H., Shau W.Y., et al. Comparative safety of inhaled medications in patients with chronic obstructive pulmonary disease: systematic review and mixed treatment comparison meta-analysis of randomised controlled trials. Thorax 2013, 68(1):48-56.
88. Wise R.A., Anzueto A., Calverley P., et al. The Tiotropium Safety and Performance in Respimat(R) Trial (TIOSPIR(R)), a large scale, randomized, controlled, parallel-group trial-design and rationale. Respir Res 2013, 14:40. 10.1186/1465-9921-14-40.
89. Calverley P.M., Rennard S., Nelson H.S., et al. One-year treatment with mometasone furoate in chronic obstructive pulmonary disease. Respir Res 2008, 9:73.
90. Martinez F.J., Boscia J., Feldman G., et al. Fluticasone furoate/vilanterol (100/25; 200/25 mug) improves lung function in COPD: a randomised trial. Respir Med 2013, 107(4):550-559.